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Abstract 
Objective 
Rifaximin-α 550 mg twice daily plus lactulose has demonstrated efficacy in reducing 
recurrence of episodes of overt HE (OHE) and the risk of HE-related hospitalisations compared 
with lactulose alone. This analysis estimated the cost effectiveness of rifaximin-α 550 mg 
twice daily plus lactulose versus lactulose alone in UK cirrhotic patients with OHE.  
Method  
A Markov model was built to estimate the incremental cost effectiveness ratio (ICER). The 
perspective was that of the UK National Health Service (NHS). Clinical data were sourced from 
a randomised controlled trial (RCT) and an open-label maintenance (OLM) study in cirrhotic 
patients in remission from recurrent episodes of OHE. Health-related utility was estimated 
indirectly from disease-specific quality of life RCT data. Resource use data describing the 
impact of rifaximin-α on hospital admissions and length of stay for cirrhotic patients with OHE 
were from four single-centre UK audits. Costs (2012) were derived from published sources; 
costs and benefits were discounted at 3.5%. The base-case time horizon was five years.  
Results  
The average cost per patient was £22,971 in the rifaximin-α plus lactulose arm and £23,545 in 
the lactulose arm, a saving of £573. The corresponding values for benefit were 2.35 QALYs and 
1.83 QALYs per person, a difference of 0.52 QALYs. This translated into a dominant base-case 
ICER. Key parameters that impacted the ICER included number of hospital admissions and 
length of stay. 
Conclusion  
Rifaximin-α 550 mg twice daily in patients with recurrent episodes of overt HE was estimated 
to generate cost savings and improved clinical outcomes compared to standard care over five 
years.  
Keywords: Hepatic Encephalopathy, Rifaximin, Cost-Utility Analysis, Cost-Benefit Analysis 
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Introduction 
Liver cirrhosis is a progressive condition associated with high morbidity and mortality. It occurs over 
a period of years in response to liver damage following exposure to one or more risk factors such as 
alcohol misuse, non-alcoholic fat liver deposition and viral infections [1]. The occurrence of 
complications in cirrhotic patients alters the natural history of liver disease, resulting in a poorer 
prognosis, greater hospital management and increased mortality [2]. One of the major complications 
of cirrhosis and most debilitating manifestations of liver disease is hepatic encephalopathy (HE), 
which is a brain dysfunction resulting from liver insufficiency or porto-systemic shunting [3]. HE is 
caused by accumulation in the bloodstream of toxins that are normally removed by the liver and it 
manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subtle 
neuropsychological alterations to coma [3]. The clinical diagnosis of HE is based on the Conn score, 
which ranges from 0 to 4, with higher scores indicating more severe mental and psychomotor 
impairment. According to the severity of the manifestation, HE can be classified as covert HE (CHE, 
Conn score 0-1) – described as subtle neuro-psychological abnormalities such as alterations in 
attention, psychomotor speed, working memory and visuospatial ability – or overt HE (OHE, Conn 
score 2-4) – ranging from clinically visible signs of confusion, space and time disorientation, 
personality change to coma [3,4]. Covert HE occurs in about 60% and OHE in about 30-40% of 
patients with cirrhosis at some point during their clinical course, and patients with a previous 
episode of OHE have a 1-year cumulative risk of recurrence of 40% [5-7]. HE may adversely affect 
lives of patients, with cumulative deficits in cognitive function and diminished health related quality 
of life (HRQoL) across both physical and mental domains[8,9]. The 1-year and 5-year mortality 
associated with HE are higher (64% and 85%) than those associated with other major complications 
of cirrhosis, such as variceal bleed (20% and 63%) and ascites (29% and 58%) [10]. The severity of 
this complication is emphasised by the strong association between history of OHE and mortality. In a 
study of patients with liver cirrhosis and a history of recurrent OHE episodes, survival rates were 
42% at one year and 23% at three years following an OHE episode [11]. The occurrence of a HE 
episode of Conn score 2 in patients with cirrhosis was associated with a 4-fold increase in mortality 
[12].  
The number of patients with HE in England and Wales remains uncertain since there is not a specific 
code for HE within the current international classification of diseases (ICD-10) schedule [13]. It is 
estimated that in England and Wales 60,000 people have cirrhosis, and of these, based on a crude 
calculation, about (60%) 36,000 may have CHE, of whom about (60%) 21,000 may develop an OHE 
episode within three years of CHE diagnosis [5,14,15]. Whilst patients in remission, or experiencing 
CHE symptoms, may be managed effectively in the community, patients experiencing an OHE 
episode are usually admitted to hospital for treatment. Recurrent HE episodes are a distressing 
aspect of chronic liver disease for both patients and their carers; they consume considerable NHS 
resources [16] and are associated with poorer prognosis [17]. Reduction in recurrence of episodes of 
OHE is therefore an important treatment goal for patients with liver cirrhosis.  
Key recommendations for the secondary prevention of OHE come from the joint 
EASL/AASLD guideline published in 2014, where rifaximin-α is recommended as add-on to lactulose 
therapy [1,3]. Rifaximin-α, a poorly absorbable, broad spectrum, oral antibiotic, is thought to inhibit 
the division of urea-deaminating bacteria, thereby reducing the intestinal production of ammonia 
and other compounds that are believed to be important to the pathogenesis of HE [18]. Following an 
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OHE event, rifaximin-α can be used for reducing the recurrence of OHE episodes in patients ≥18 
years. 
In the pivotal randomised controlled trial (RCT) of rifaximin-α (RFHE001), patients with 
chronic liver disease and in remission from at least two OHE episodes (Conn score 0 or 1) were 
randomly allocated to receive rifaximin-α 550 mg twice daily or placebo for 6 months; 91% of 
patients in both groups received concomitant lactulose [19]. Rifaximin-α was found to significantly 
reduce the risk of an OHE episode and HE-related hospitalisations compared with placebo, with 
significant improvements also demonstrated in HRQoL [9,19]. An open-label maintenance (OLM) 
study (RFHE002, extension of the RCT) conducted over 24 months to examine the longer term 
impact of rifaximin-α, demonstrated a continued reduction in the rate of HE-related and all-cause 
hospitalisations with rifaximin-α use, together with a well-tolerated safety profile [20]. 
In March 2015, the National Institute for Health and Care Excellence (NICE) published 
guidance, Technology Appraisal 337 (TA 337), recommending rifaximin-α use within its marketing 
authorization [21]. The original submission in 2013 was centred on both the clinical effectiveness 
and cost-effectiveness of rifaximin-α assessed on findings from the pivotal RCT [19]. Subsequent to 
the original submission, real world data from four individual UK audits became available [22-25] and 
were included as an addendum in the NICE submission of 2014.  
The purpose of this analysis is to provide a clearer determination of the value for money of 
rifaximin-α for treating people with HE using trial data and real world evidence used in the NICE TA 
337.  
Methods 
Evaluation approach 
A cost-effectiveness analysis of the use of rifaximin-α plus optional concomitant lactulose versus 
placebo plus optional concomitant lactulose was undertaken using a Markov state transition model. 
The specified model structure captured clinical outcomes that would be observed in current 
practice: time to first breakthrough OHE episode, aligned with the pivotal RCT’s primary outcome 
[19], and subsequent breakthrough of HE episodes following periods of remission. A cohort of 1,000 
patients was entered into both arms of the model. This cohort consisted of adult cirrhotic patients in 
remission (Conn score 0-1) from recurrent OHE episodes (at least two prior episodes), reflecting the 
patient characteristics of those enrolled in the pivotal RCT [19]. The treatment arms in the model 
were also aligned to this same study, where patients received rifaximin-α 550 mg twice daily with or 
without lactulose or placebo with or without lactulose; in the pivotal RCT, 91% of patients in both 
arms were taking concomitant lactulose [19]. 
The analysis was undertaken from the perspective of the UK National Health Service. The 
base-case time horizon was five years, which reflects the typical life expectancy of patients with 
cirrhosis and a history of OHE [10,11]. The cycle length was one month, in line with the interval at 
which data were collected during the pivotal RCT, and was considered sufficiently short to avoid 
over-estimating outcomes and resource use, thus no half-cycle correction was applied. Health 
effects were measured in quality adjusted life years (QALYs), using the Chronic Liver Disease 
Questionnaire (CLDQ) mapped to EuroQol five dimensions questionnaire (EQ-5D). The discount rate 
was 3.5% for both benefits and costs as recommended by the Treasury [26]. Prices are in 2012 prices 
(UK £). The values for key variables used in the model are detailed in Table 1. 
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Model structure and key features 
The costs and benefits of the introduction of rifaximin-α were estimated using a state transition 
approach that reflected the clinical pathway of patients with liver disease and recurrent OHE, where 
OHE episodes alternate with remission periods (Figure 1). The model comprised five health states: 
(1) CHE 1 (CHE-1) – The model starting state. Patients in this state were in remission from a 
previous OHE event (Conn score 0 or 1) 
(2) OHE 1 (OHE-1) – The first breakthrough episode of OHE (Conn grade 2, 3 or 4) following 
model start. Whilst in OHE 1 patients were at risk of hospitalisation 
(3) CHE 2 (CHE-2) – Remission state post OHE 1 and all subsequent OHE events 
(4) OHE 2 (OHE-2) – Captured all subsequent episodes of OHE following model start. Whilst in 
OHE-2 patients were at risk of hospitalisation 
(5) Death – Captured death of patients from CHE-1, OHE-1, CHE-2 and OHE-2 states 
Patients entered the model in a covert state, CHE-1, and transitioned to the overt state OHE-
1 when experiencing a breakthrough episode of OHE. Following a breakthrough episode, patients in 
OHE-1 would enter into a subsequent remission state, CHE-2, and would remain there pending 
subsequent episodes of HE during which they would transition to OHE-2. Following resolution of the 
OHE episode, patients would transition from OHE-2 back to CHE-2 where they would be at risk of 
further OHE events captured as transitions into OHE-2. From each of these states (CHE-1, OHE-1, 
CHE-2, OHE-2) patients could exit the model in case of death.  
 
Key model transition probabilities 
Transition probabilities applied in the analysis were derived from the RCT [19], from 
unpublished individual patient level data from the follow-up OLM study [20], and from a post-hoc 
analysis of the OLM trial [20] (Table 1); patient characteristics of the OLM study have been published 
[20]. Time to first breakthrough OHE episode for the rifaximin-α and placebo arms were extracted 
from a Kaplan-Meier (KM) analysis from the pivotal RCT for the period 0 to 168 days [19]. 
Unpublished patient level data for rifaximin-α patients who did not experience a breakthrough OHE 
event during the RCT phase [19] and were enrolled in the OLM study [20] were used to derive a KM 
curve for first breakthrough OHE event from 168 to 1008 days. These two datasets were combined 
and parametric survival distributions were fitted. Akaike information criterion (AIC), Bayesian 
information criterion (BIC) and visual inspections were also consulted to determine best model fit, 
resulting in selection of a lognormal distribution. The model assumed full recovery after 30.4 days 
following a breakthrough OHE episode, where patients re-entered a subsequent covert state (CHE-2) 
after one cycle; this assumption was applied for all OHE events. Patients in the remission state 
following an OHE event (CHE-2) were at risk of further OHE events. To estimate the transition 
between CHE-2 and OHE-2, unpublished patient level data were used to estimate the time to the 
first subsequent OHE event (i.e. the second event following entry into the RCT or OLM). The same 
methods (described above) used to derive the transition probabilities for time to first breakthrough 
event were applied to derive subsequent OHE events. The process found that the lognormal 
distribution provided the best fit for time to subsequent OHE events. The risk of an OHE episode was 
found to be greater in CHE-2 than when patients entered the model in CHE-1. Patients in the CHE-2 
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state were at risk of having further OHE episodes and, in the current model, the transition 
probability applied for all other subsequent OHE events was assumed to be the same as that applied 
for the first subsequent OHE event. This is likely to be a conservative assumption as risk of further 
OHE events increases with the number of prior OHE events [17].  
 
Mortality 
The model inputs for mortality in the four health states (CHE-1, CHE-2, OHE-1 and OHE-2) were the 
same for the rifaximin-α and lactulose cohorts.  
Patients were at risk of both HE-related mortality and all-cause mortality in all model cycles. 
Data from a post-hoc analysis of the OLM study were sourced to characterise disease-related 
mortality [17]. The baseline mortality in the model was the additive combination of the HE-related 
and all-cause mortality.  
The mean age of the patient population under consideration in the pivotal study was 56 
years, and this was adopted in the base-case analysis [19].  Patients in the model were assumed to 
have a baseline risk of all-cause mortality given their mean age and underlying health status. General 
population, age-related mortality rates were converted to monthly probability of death by age from 
Interim Life Tables for England and Wales by the Office of National Statistics [27]. Mortality risk was 
adjusted to incorporate the weighted average of the ratio of males to females in the original RCT 
[19]. Disease related mortality inputs were obtained by using the best-fit parametric proportional 
hazards survival models from the OLM [20]. In the CHE-1 state the best fit was found to be a log 
normal distribution and in the CHE-2 state a Weibull distribution [17]. The probability of mortality 
was higher in the CHE 2 state compared to CHE1 state. The 30-day mortality risk associated with the 
first breakthrough episode of HE (OHE-1) and subsequent OHE episode (OHE-2) were 11.0% 
(standard error (SE) 0.03) and 7.7% (SE 0.02), respectively. These mortality rates were calculated 
from the OLM study [20], and adjusted to include all-cause mortality.  
 
Hospitalisation and length of stay 
Results from a meta-analysis using data from four individual UK centres [22-25] investigating the 
impact of treatment with rifaximin-α on hospital resources in UK clinical practice were used for 
hospitalisations and length of stay in the model [21,28]. These interim data were subsequently 
validated in a more comprehensive study of a larger number of UK centres [16]. Two endpoints were 
analysed, hospitalisations and total bed days. A constant event rate was assumed in annualising the 
data presented by each study, which had varying observation periods. Mean difference in each 
primary endpoint was tested with a continuous random-effects model using the DerSimonian-Laird 
method to allow for heterogeneity between studies. A mean difference of 22.2 (95% CI; 9.1-35.3; 
p<0.001) annual bed days per patient before and after rifaximin-α was observed. A mean difference 
of 1.3 (0.7-1.8; p<0.001) annual hospitalizations per patient before and after rifaximin-α was 
observed. The reduction of 44% in hospitalizations and 66% reduction in bed days were 
implemented in the model [28]. 
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Health-related utility 
Health-related utility was estimated indirectly from disease-specific quality of life data (CLDQ) 
collected from the pivotal study [29]. These data showed that during the covert/remission state 
there were significant improvements in the health-related QoL (HRQoL) of patients in the rifaximin-α 
plus lactulose group compared with patients taking placebo plus lactulose [9]. The relationship 
between the disease-specific (CLDQ) [30] and generic HRQoL(EQ-5D) data can be seen in Figure 
2[29]. In the lactulose group, patients in CHE-1 and CHE-2 had a utility value of 0.588. Patients 
treated with rifaximin-α had an incremental change in EQ-5D of 0.106 relative to the lactulose 
group. This utility increment was applied in the model for both the CHE-1 and CHE-2 states for 
rifaximin-α treated patients. In both model arms, patients in OHE-1 and OHE-2 had a utility value of 
0.538 The utility values applied in the model were adjusted to incorporate the effect of ageing. The 
average age of the modelled cohort was extracted from the pivotal RCT [19]. UK population norms 
were extracted from Kind and colleagues (Table 1) [31].  
 
Financial costs 
The drug acquisition costs used in the model were based on published costs from the British 
National Formulary for lactulose and for rifaximin-α [32]. The dosage of rifaximin-α was one 550 mg 
tablet twice daily. The unit price of a 56-tablet pack of rifaximin-α was £259.23 (Table 1). The 
recommended starting dose for lactulose is 30 to 50 mL three times daily, and subsequently 
adjusted to produce two to three soft stools daily. The dose was taken from the published RCT [19]. 
The mean dose of concomitant lactulose was 3.14 cups per day for patients on rifaximin-α and 3.51 
cups per day for patients on placebo (1 cup is 10 g lactulose/15 mL). Given that the price of lactulose 
was £2.28 per 500 mL, the cost of concomitant lactulose is calculated as £6.54 per month for 
patients on rifaximin-α and £7.31 per month for patients on placebo. Patients were assumed to 
receive medication over the entirety of the modelled time horizon. 
Expert opinion, sought to determine the frequency of outpatient visits for patients in 
remission, suggested that patients were reviewed every 3-6 months in an outpatient setting. Based 
on NHS Reference Costs, the unit cost for an outpatient visit was £176.27, and with a frequency of 
outpatient visits assumed to be every three months (base-case analysis), the total cost applied in the 
model for the remission health state was £58.75 per month [33].  
In the OHE state, the model assumed that all patients incurred the cost of an additional 
outpatient visit (£176.27) [33]. Furthermore, those patients who had a hospitalisation incurred 
additional costs. To estimate the cost per day in the OHE state, a weighted average of all non-
elective inpatient (long stay) HRG procedure codes beginning with GC from NHS Reference Costs was 
used [33]. These reference costs were applied to the duration of stay calculated in the meta-analysis 
described above. The total cost for a patient in the overt health state was £10,180 and £6,779 for 
rifaximin-α and placebo, respectively (Table 1). 
  
Sensitivity and scenario analysis 
Deterministic and probabilistic sensitivity analysis was undertaken on all variables using the values 
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and distributions outlined in Table 1. A scenario analysis was run applying health state utility values 
derived from SF-36 trial data mapped to SF-6D utility values.  
 
Results 
Likelihood of being in a key clinical state  
At three years, of the 1000 patients that entered the model, 42.7% of patients assigned to the 
placebo plus lactulose arm were in the CHE2 state; this was 6.9% higher than the corresponding 
number in the rifaximin-α plus lactulose arm. At the same time point, 60.4% of rifaximin-α-treated 
patients had experienced a breakthrough OHE event compared to 79.4% of the placebo-treated 
patients. Of the patients that entered the model, 34.0% and 41.7% had died at three years in the 
rifaximin-α and placebo arms respectively. 
Differences in mortality arose from the reduced numbers of OHE episodes in the rifaximin-α 
group by two mechanisms, avoidance of the acute 30-day mortality associated with OHE-1 and OHE-
2[8], and longer retention in the CHE-1 state with exposure to a lower hazard of death than 
equivalent cases who transition to the CHE-2 state having recovered from OHE-1. 
 
Incremental cost-effectiveness ratio values for the base case scenario (5 years), and at 
alternative time horizons  
The average cost for the included elements of care at five years was £22,971 in the  
rifaximin-α arm and £23,545 in the lactulose arm, a cost saving of £573. The corresponding values 
for benefit were 2.35 QALYs and 1.83 QALYs per person, respectively, a difference of 0.52 QALYs. 
This translated into a dominant base-case scenario (i.e. lower costs and improved health outcomes). 
The ICER at two years was also dominant. Whilst only a small number of subjects will survive more 
than five years because they are so severely ill, it was possible to generate a theoretical ICER value at 
10 years (£4,470 per QALY gained, 3.43 years on rifaximin), and running the model to a lifetime 
horizon (£7,215 per QALY gained, 4.42 years on rifaximin-α) (Table 2).  
Sensitivity analysis 
Deterministic sensitivity analysis illustrates that the model was insensitive to most parameters 
(Figure 3). Varying the real-world data by using the 95% confidence interval around the mean 
difference in bed days per person per year resulted in a mean ICER of  
-£17,014 (dominant) per QALY gained and £17,168 per QALY gained. Since rifaximin-α has been 
shown to reduce both the frequency of hospital admission and the length of hospital stay, variation 
in this factor has a notable impact on the base case ICER [16]. Following this, the parametric 
distribution of rate of progression to OHE was found to exert influence on model results.     
A probabilistic sensitivity analysis is illustrated in the cost effectiveness plane (Figure 4). 
Here not all results are dominant but the likelihood of rifaximin-α being cost effective at the 
conventional level of £30,000 per QALY gained was >99%.   
Ac
ce
pte
d M
an
us
cri
pt
9 
 
When SF-6D utility data were applied in the model a higher number of QALYs were 
generated in the rifaximin-α and lactulose arm of the model (2.563 QALYs) compared with the 
rifaximin-α and lactulose arm (1.753 QALYs). Total costs in each arm were unchanged and 
consequently rifaximin-α plus lactulose was dominant when compared to placebo plus lactulose. 
Discussion 
Patients in the morbid phase of end stage liver failure are severely ill, with low life expectancy, 
unless in receipt of a successful liver transplant. HE, one of the major complications of advanced 
liver disease, is both difficult to manage and financially costly. The present health economic 
evaluation shows that the use of rifaximin-α to reduce the recurrence of OHE episodes improves 
clinical outcomes and is cost saving. In economic parlance, rifaximin-α in combination with lactulose 
is dominant over standard care with lactulose alone.  
The economic model presented was based on the six month rifaximin-α registration study, 
unpublished analyses of patient level data from the OLM study conducted over 24 months, and the 
post-hoc analysis of the OLM [17,19,20]. Health-related utility was estimated indirectly from disease-
specific quality of life data from the pivotal study [9], while resource use data describing the impact 
of rifaximin-α on hospital admissions and length of stay within the NHS were from single-centre UK 
audits [22-25]. From the clinical data analysed, it was clear that repeated OHE episodes can 
adversely affect patients’ quality of life and yield significant burden on healthcare resources. The 
present health economic analysis demonstrated that add-on rifaximin-α to lactulose for 
management of patients with history of OHE is a cost-effective option, because, by reducing the 
number of OHE episodes as well as hospital admissions and stay, rifaximin-α improves patients 
quality of life and reduces the overall costs associated with the care of these patients. In particular, 
the average cost per patient for the included elements of care was £22,971 in the rifaximin-α plus 
lactulose arm and £23,545 in the lactulose alone arm, with a saving of £573. The corresponding 
values for benefit were 2.35 QALYs and 1.83 QALYs per patient, respectively, with a difference of 
0.52 QALYs. This translated into a dominant base-case ICER over the 5-year horizon. Furthermore, in 
our analysis the cost-effectiveness of rifaximin-α was found to be robust following a range of 
methods of examining the sensitivity of the resulting ICER to factors that were known to be 
uncertain. 
From the analysis of patient level data, it was clear that repeated OHE episodes can have a 
significant impact on the mortality of patients, since being in the overt state increases your chance 
of death. By modelling this effect, our analysis estimated the importance of using rifaximin-α to 
reduce recurrent OHE episodes in patients with history of OHE.  
As in all economic evaluations of this nature, this model was the result of the distillation of a 
range of data from various sources. As highlighted by deterministic sensitivity analysis (Figure 3) our 
summary value of dominance is heavily influenced by the results from a meta-analysis [28] of four 
individual UK audits [22-25] that estimated a 44% reduction in annualised bed days per patient 
treated with rifaximin-α compared to standard of care. This finding was supported by recently 
published real world data from a retrospective, multicentre study of 7 UK hospitals, that found a 
reduction in hospital length of stay ranging from 31% (annualised data) to 53% (3-month data) 
following initiation of rifaximin-α. This resulted in an annual cost saving between £1,480 and £3,228 
per patient when taking into account drug costs for 1-year rifaximin-α treatment [16].  
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Clinical benefits of rifaximin-α over-and-above an evident reduction in the risk of OHE events 
have been postulated [17]. Questions now remain about how early these benefits could be achieved 
by managing patients earlier in the natural history of their liver disease. 
Conclusion 
Rifaximin-α 550 mg twice daily in patients with recurrent HE in the context of liver cirrhosis not only 
produced clinical benefits resulting in improved health related utility, but also represented good 
value for money compared to standard care by reducing episodes of OHE and associated hospital 
resource use. 
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Table 1. Key parameters included in the evaluation. 
Variable Value Lower 
CI 
Upper CI Distribut
ion 
Source 
Dosage      
   Average daily dose of lactulose - 
placebo arm 
52.65 52.25 53.05 Normal RFHE3001 
(19) 
   Average daily dose of lactulose - 
rifaximin arm 
47.10 46.75 47.45 Normal RFHE3001 
Costs      
   Rifaximin tablet price £4.63 4.63 4.63 None BNF 63  
   Lactulose price (500 mL) £2.28 2.28 2.28 None BNF 63 
   Cost of outpatient visit £110.68 £110.51 £110.84 Gamma NHS ref. 
cost(33) 
   Liver Failure Disorders with 
Interventions 
£3,483.8
6 
£3,235.
97 
£3,731.75 Gamma NHS ref. 
cost(33) 
   Liver Failure Disorders without 
Interventions 
£2,028.4
2 
£1,922.
02 
£2,134.83 Gamma NHS ref. 
cost(33) 
   Non-Malignant Liver Disorders with 
Catastrophic CCs 
£3,988.2
6 
£3,700.
39 
£4,276.14 Gamma NHS ref. 
cost(33) 
   Non-Malignant Liver Disorders with 
Severe CCs 
£3,084.0
7 
£2,882.
30 
£3,285.83 Gamma NHS ref. 
cost(33) 
   Non-Malignant Liver Disorders with 
Major CCs 
£2,421.0
8 
£2,320.
36 
£2,521.80 Gamma NHS ref. 
cost(33) 
   Non-Malignant Liver Disorders without 
Major CCs 
£1,795.2
6 
£1,715.
41 
£1,875.12 Gamma NHS ref. 
cost(33) 
Hospitalisations      
   Percentage hospitalised - placebo arm 100% 100% 100% None UK RWD 
(28)  
   Percentage hospitalised - rifaximin arm 100% 100% 100% None UK RWD 
(28) 
   Length of stay - days (placebo) 30.6 30.6 30.6 None UK RWD 
(28) 
   Percentage reduction in LOS (rifaximin) 34% -40.5% 99% None UK RWD 
(28) 
      1
st
 episode      
         Lognormal regression treatment 
parameter 
1.10 0.57 1.62 None RFHE3001 
PLD 
         Lognormal regression constant 
parameter 
1.80 1.45 2.14 None RFHE3001 
PLD 
         Lognormal regression /ln_sig 
parameter 
0.62 0.47 0.77 None RFHE3001 
PLD  
       Subsequent episode      
         Lognormal regression treatment 
parameter 
-1.09 -1.62 -0.56 None RFHE3002 
PLD 
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Variable Value Lower 
CI 
Upper CI Distribut
ion 
Source 
         Lognormal regression constant 
parameter 
1.38 0.99 1.77 None RFHE3002 
PLD  
         Lognormal regression /ln_sig 
parameter 
0.55 0.37 0.74 None RFHE3002 
PLD 
 Health-related utility      
   Duration of HE episode disutility – days 11 1 28 Normal KOL ad-
board 
   EQ-5D population norm (all population) 0.86 0.85226 0.86774 Normal 
UK 
Population 
Norms for 
EQ-5D 
(31) 
   EQ-5D population norm (population 
aged <25) 
0.94 0.92651 0.95349 Normal 
   EQ-5D population norm (population 
aged 25-34) 
0.93 0.91929 0.94071 Normal 
   EQ-5D population norm (population 
aged 35-44) 
0.91 0.89676 0.92324 Normal 
   EQ-5D population norm (population 
aged 45-54) 
0.85 0.81440 0.88560 Normal 
   EQ-5D population norm (population 
aged 55-64) 
0.80 0.77684 0.82316 Normal 
   EQ-5D population norm (population 
aged 65-74) 
0.78 0.75693 0.80307 Normal 
   EQ-5D population norm (population 
aged 75+) 
0.73 0.70014 0.75986 Normal 
   CLDQ-EQ5D conversion factor 0.143 0.131 0.154 Normal RFHE3001 
PLD(29) 
   CLDQ rifaximin-increment 0.743 0.182 1.303 Normal Sanyal 
2011(9) 
   SF-36 baseline utility  0.568 0.539 0.597 Beta RFHE3001 
PLD 
   SF-36 baseline-adjusted rifaximin-utility 
increment 
0.190 0.179 0.200 Normal RFHE3001 
PLD 
Mortality      
   Lognormal regression constant 
parameter (covert) 
5.36 4.38 6.35 None RFHE3002 
PLD 
   Lognormal regression /ln_sig 
parameter (covert) 
0.65 0.33 0.97 None RFHE3002 
PLD 
   30-day prob (overt) 0.11 0.06 0.16 Beta RFHE3002 
(20) 
   Weibull regression constant parameter 
(sub-covert) 
-3.62 -4.36 -2.88 None RFHE3002 
PLD 
   Weibull regression /ln_sig parameter 
(sub-covert) 
0.80 0.56 1.14 None RFHE3002 
PLD 
   30-day prob (sub-overt) 0.08 0.04 0.11 Beta RFHE3002 
(20) 
  MVN: multi-variate normal   
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Table 2. Incremental cost effectiveness ratio (ICER) at varying time horizons. 
Time horizon 
Lactulose 
 
Rifaximin 
    QALY Cost  
 
QALY Cost 
 
∆ QALY ∆ Costs ICER 
2 years 0.97 £16,852 
 
1.20 £13,170 
 
0.23 -£3,681 -£15,916 
5 years 1.83 £23,545 
 
2.35 £22,971 
 
0.53 -£573 -£1087 
10 years 2.58 £27,330 
 
3.43 £31,153 
 
0.86 £3,823 £4,470 
Lifetime 3.19 £29,552 
 
4.42 £38,432 
 
1.23 £8,880 £7,215 
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